CDKN2A and neoplasm: Regarding the impacts of p16 promoter hypermethylation (PHM) on CRC, some investigations revealed a correlation between it and some clinicopathological parameters or poor prognosis [10–14, 16], such as p16 PHM with larger tumor size, more frequent recurrence and shortened survival.